P345	Increased levels of IgG1 against an aldehyde-modified peptide sequence in apo B–100 is associated with decreased severity of carotid stenosis.
1G.N.Fredrikson, 1G.Berglund, 1R.Alm, 1J-Å.Nilsson, 1A.Schiopu, 2P.K.Shah, 1J.Nilsson, the participants in this study
1Department of Clinical Sciences, Malmö, SE; 2Atherosclerosis Research Center, Cedars-Sinai Medical Center, Los Angeles, US.

Objective: Immunization with a malondialdehyde (MDA)-modified peptide corresponding to the amino acid sequence between 661 and 680 in apoB-100 (p45) has been shown to inhibit atherosclerosis in apo E knockout mice. Similar results are seen following treatment of mice with human recombinant anti-MDA-p45 IgG1. In the present study we tested the hypothesis that endogenous levels of IgG to MDA-p45 would be associated with reduced carotid atherosclerosis and cardiovascular events in man. Methods and Results: Using a nested case control design we analyzed plasma MDA-p45 IgG1, IgG2, IgG3 and IgG4 levels in baseline samples from 76 subjects with coronary events and 148 matched controls recruited from the prospective Malmö Diet Cancer study. Baseline percent carotid stenosis, common carotid artery and bulb intima-media thickness were determined by B-mode ultrasound. There were no differences in antibody levels between cases and controls. However, a significant association was found between high levels of MDA-p45 IgG1 and a low degree of carotid stenosis (p=0.006 following adjustment for age, sex, blood pressure, low and high density lipoprotein cholesterol). Conclusions: The finding of an inverse association between MDA-p45 IgG1 and severity of carotid stenosis in humans supports previous experimental studies suggesting that these antibodies have an atheroprotective effect.

Copyright © 2005 S. Karger AG, Basel. Any further use of this abstract requires written permission from the publisher.